BMO says Eylea court decision ‘modest negative’ for Regeneron
BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...
Investopedia24d
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea. Teva and Alvotech have been working together in a strategic partnership since 2020. Teva Pharmaceutical ...
Yahoo Finance25d
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...
pharmaphorum1d
4DMT gene therapy cuts need for Eylea in wet AMD trial
They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.
Nasdaq1mon
Regeneron Reports Positive Three-Year Results for EYLEA HD Treatment in Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).
Seeking Alpha24d
Teva and Alvotech get FDA review acceptance for its proposed biosimilar to Eylea
The trial, designed to compare the efficacy, safety, and immunogenicity of AVT06 with Eylea, reached the main goal, according to its topline data from January 2024. The duo said the FDA process to ...